These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 31251343)

  • 1. A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
    Chung MJ; Cho WK; Oh D; Eom KY; Kim JH; Kim WC; Lee JH
    J Radiat Res; 2019 Oct; 60(5):677-684. PubMed ID: 31251343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.
    Lee JW; Oh D; Eom KY; Kim JH; Kim WC; Chung MJ; Lee JH
    Clin Exp Metastasis; 2020 Feb; 37(1):125-131. PubMed ID: 31555945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
    Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
    Chan EHL; Koh LP; Lee J; De Mel S; Jeyasekharan A; Liu X; Tang T; Lim ST; Tao M; Quek R; Farid Bin Harunal Ras M; Lee YS; Diong C; Tan D; Kim SJ; Chee YL; Poon LMM
    Cancer Med; 2019 Aug; 8(10):4626-4632. PubMed ID: 31264808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.
    Lamy T; Damaj G; Soubeyran P; Gyan E; Cartron G; Bouabdallah K; Gressin R; Cornillon J; Banos A; Le Du K; Benchalal M; Moles MP; Le Gouill S; Fleury J; Godmer P; Maisonneuve H; Deconinck E; Houot R; Laribi K; Marolleau JP; Tournilhac O; Branger B; Devillers A; Vuillez JP; Fest T; Colombat P; Costes V; Szablewski V; Béné MC; Delwail V;
    Blood; 2018 Jan; 131(2):174-181. PubMed ID: 29061568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
    Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma.
    Shin DY; Byun BH; Kim KM; Kang JH; Lim I; Kim BI; Lee SS; Choi CW; Kang HJ; Lim SM
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):825-31. PubMed ID: 27577259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.
    Freeman CL; Savage KJ; Villa DR; Scott DW; Srour L; Gerrie AS; Brown MJ; Slack GW; Farinha P; Skinnider B; Morris J; Bénard F; Aquino-Parsons C; Lo A; Pickles T; Wilson DC; Tonseth P; Connors JM; Sehn LH
    Blood; 2021 Feb; 137(7):929-938. PubMed ID: 32871586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
    Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Kang HJ; Lee HH; Jung SE; Park KS; O JH; Jeon YW; Choi BO; Cho SG
    PLoS One; 2020; 15(9):e0238807. PubMed ID: 32960887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
    Tomita N; Takasaki H; Miyashita K; Fujisawa S; Ogusa E; Matsuura S; Kishimoto K; Numata A; Fujita A; Ohshima R; Kuwabara H; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Fujimaki K; Taguchi J; Sakai R; Ishigatsubo Y
    Br J Haematol; 2013 May; 161(3):383-8. PubMed ID: 23432318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.